drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00472 | DB11057 | 758 | 720 | [
"DDInter758",
"DDInter1223"
] | Fluoxetine | Mineral oil | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
758,
24,
720
]
],
[
[
758,
24,
927
],
[
927,
63,
720
]
],
[
[
758,
24,
1151
],
[
1151,
24,
720
]
],
[
[
758,
25,
1069
],
[
1069,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Suni... |
DB00307 | DB01610 | 1,101 | 248 | [
"DDInter202",
"DDInter1912"
] | Bexarotene | Valganciclovir | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
1101,
24,
248
]
],
[
[
1101,
24,
563
],
[
563,
1,
248
]
],
[
[
1101,
21,
29209
],
[
29209,
60,
248
]
],
[
[
1101,
24,
510
],
[
510,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Bexarotene (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Valganciclovir (Compound)
Bexarotene may cause a moderate inte... |
DB00649 | DB08904 | 231 | 375 | [
"DDInter1710",
"DDInter342"
] | Stavudine | Certolizumab pegol | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Moderate | 1 | [
[
[
231,
24,
375
]
],
[
[
231,
24,
1047
],
[
1047,
24,
375
]
],
[
[
231,
24,
1434
],
[
1434,
63,
375
]
],
[
[
231,
63,
10
],
[
10,
2... | [
[
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine... | Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Stavudine may cause a moderate interaction that could exacerbate diseases when take... |
DB00835 | DB05541 | 100 | 801 | [
"DDInter245",
"DDInter239"
] | Brompheniramine | Brivaracetam | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 . | Moderate | 1 | [
[
[
100,
24,
801
]
],
[
[
100,
63,
475
],
[
475,
24,
801
]
],
[
[
100,
35,
1376
],
[
1376,
24,
801
]
],
[
[
100,
24,
1264
],
[
1264,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brivaracetam"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
]... | Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Brivaracetam
Brompheniramine (Compound) resembles Diphenhydramine (Compound) and Brompheniramine may cause a moderate inte... |
DB00819 | DB09112 | 471 | 1,455 | [
"DDInter15",
"DDInter1306"
] | Acetazolamide | Nitrous acid | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
471,
24,
1455
]
],
[
[
471,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
471,
24,
433
],
[
433,
63,
1455
]
],
[
[
471,
63,
1061
],
[
1061,
... | [
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
... | Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Ertugli... |
DB01023 | DB06663 | 409 | 1,154 | [
"DDInter716",
"DDInter1398"
] | Felodipine | Pasireotide | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
409,
24,
1154
]
],
[
[
409,
63,
966
],
[
966,
40,
1154
]
],
[
[
409,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
409,
40,
84
],
[
84,
... | [
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
... | Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide (Compound) resembles Pasireotide (Compound)
Felodipine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Felodipine (Compound) resembles ... |
DB00476 | DB00736 | 109 | 660 | [
"DDInter608",
"DDInter676"
] | Duloxetine | Esomeprazole | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Minor | 0 | [
[
[
109,
23,
660
]
],
[
[
109,
62,
1215
],
[
1215,
40,
660
]
],
[
[
109,
23,
379
],
[
379,
40,
660
]
],
[
[
109,
62,
837
],
[
837,
1... | [
[
[
"Duloxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Esomeprazole"
]
],
[
[
"Duloxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lansoprazole"
],
[
... | Duloxetine may cause a minor interaction that can limit clinical effects when taken with Lansoprazole and Lansoprazole (Compound) resembles Esomeprazole (Compound)
Duloxetine may cause a minor interaction that can limit clinical effects when taken with Rabeprazole and Rabeprazole (Compound) resembles Esomeprazole (Comp... |
DB00994 | DB01133 | 361 | 1,104 | [
"DDInter1277",
"DDInter1808"
] | Neomycin | Tiludronic acid | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Tiludronate, or (4-chlorophenyl)thio-methylene-1,1-bisphosphonate, is a first generation bisphosphonate similar to [etidronic acid] and [clodronic acid].[A1923,A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. Tiludronic acid was first described ... | Moderate | 1 | [
[
[
361,
24,
1104
]
],
[
[
361,
21,
28809
],
[
28809,
60,
1104
]
],
[
[
361,
24,
1448
],
[
1448,
24,
1104
]
],
[
[
361,
64,
544
],
[
544,
... | [
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiludronic acid"
]
],
[
[
"Neomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is cau... | Neomycin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Tiludronic acid (Compound)
Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Ti... |
DB00108 | DB14962 | 1,066 | 1,363 | [
"DDInter1268",
"DDInter1847"
] | Natalizumab | Trastuzumab deruxtecan | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes i... | Major | 2 | [
[
[
1066,
25,
1363
]
],
[
[
1066,
24,
1430
],
[
1430,
24,
1363
]
],
[
[
1066,
25,
384
],
[
384,
24,
1363
]
],
[
[
1066,
64,
599
],
[
599,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab deruxtecan"
]
],
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
... | Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab deruxtecan
Natalizumab may lead to a major life threatening interaction when taken with Idelalisib and Ide... |
DB01136 | DB12015 | 772 | 1,033 | [
"DDInter305",
"DDInter53"
] | Carvedilol | Alpelisib | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
772,
24,
1033
]
],
[
[
772,
24,
1254
],
[
1254,
24,
1033
]
],
[
[
772,
63,
1144
],
[
1144,
24,
1033
]
],
[
[
772,
24,
1017
],
[
1017,
... | [
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
... | Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Nateglin... |
DB01229 | DB05773 | 973 | 1,047 | [
"DDInter1378",
"DDInter1848"
] | Paclitaxel (protein-bound) | Trastuzumab emtansine | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
973,
24,
1047
]
],
[
[
973,
64,
1091
],
[
1091,
24,
1047
]
],
[
[
973,
25,
375
],
[
375,
63,
1047
]
],
[
[
973,
24,
381
],
[
381,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Paclitaxel may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Pac... |
DB00581 | DB11730 | 355 | 351 | [
"DDInter1018",
"DDInter1588"
] | Lactulose | Ribociclib | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
355,
24,
351
]
],
[
[
355,
24,
1486
],
[
1486,
24,
351
]
],
[
[
355,
63,
1251
],
[
1251,
24,
351
]
],
[
[
355,
23,
286
],
[
286,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Mirtaza... |
DB00041 | DB00594 | 1,648 | 863 | [
"DDInter38",
"DDInter68"
] | Aldesleukin | Amiloride | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions... | Moderate | 1 | [
[
[
1648,
24,
863
]
],
[
[
1648,
24,
708
],
[
708,
63,
863
]
],
[
[
1648,
24,
1061
],
[
1061,
24,
863
]
],
[
[
1648,
25,
593
],
[
593,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil a... |
DB00305 | DB01005 | 377 | 995 | [
"DDInter1232",
"DDInter894"
] | Mitomycin | Hydroxyurea | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Moderate | 1 | [
[
[
377,
24,
995
]
],
[
[
377,
21,
28845
],
[
28845,
60,
995
]
],
[
[
377,
23,
1299
],
[
1299,
23,
995
]
],
[
[
377,
23,
945
],
[
945,
... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Mitomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema"
],
[
"Oedema",
"{u} (Side Effect) is caused by {... | Mitomycin (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Hydroxyurea (Compound)
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Hydroxyurea
... |
DB01331 | DB09268 | 1,558 | 1,662 | [
"DDInter325",
"DDInter1464"
] | Cefoxitin | Picosulfuric acid | Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by <i>Streptomyces lactamdurans</i>. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1558,
24,
1662
]
],
[
[
1558,
63,
597
],
[
597,
24,
1662
]
],
[
[
1558,
40,
1402
],
[
1402,
24,
1662
]
],
[
[
1558,
1,
1087
],
[
1087,... | [
[
[
"Cefoxitin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cefoxitin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]... | Cefoxitin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cefoxitin (Compound) resembles Cefotetan (Compound) and Cefotetan may cause a moderate interacti... |
DB00574 | DB01175 | 121 | 318 | [
"DDInter717",
"DDInter672"
] | Fenfluramine | Escitalopram | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Major | 2 | [
[
[
121,
25,
318
]
],
[
[
121,
64,
1230
],
[
1230,
1,
318
]
],
[
[
121,
24,
1419
],
[
1419,
23,
318
]
],
[
[
121,
24,
760
],
[
760,
... | [
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Citalopram",
... | Fenfluramine may lead to a major life threatening interaction when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a minor interaction that can limit clinical ef... |
DB00619 | DB06589 | 1,419 | 1,250 | [
"DDInter909",
"DDInter1400"
] | Imatinib | Pazopanib | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1419,
24,
1250
]
],
[
[
1419,
6,
13926
],
[
13926,
45,
1250
]
],
[
[
1419,
18,
5587
],
[
5587,
46,
1250
]
],
[
[
1419,
21,
29203
],
[
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"PIP4K2C"
],
[
"PIP4K2C",
"{u} (Gene) is bound by {v} (Compound)",
... | Imatinib (Compound) binds PIP4K2C (Gene) and PIP4K2C (Gene) is bound by Pazopanib (Compound)
Imatinib (Compound) downregulates SCAND1 (Gene) and SCAND1 (Gene) is upregulated by Pazopanib (Compound)
Imatinib (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Si... |
DB00860 | DB11652 | 891 | 1,155 | [
"DDInter1513",
"DDInter1891"
] | Prednisolone | Tucatinib | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
891,
24,
1155
]
],
[
[
891,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
891,
23,
659
],
[
659,
24,
1155
]
],
[
[
891,
24,
609
],
[
609,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilante... |
DB00372 | DB00691 | 999 | 1,058 | [
"DDInter1793",
"DDInter1237"
] | Thiethylperazine | Moexipril | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Moderate | 1 | [
[
[
999,
24,
1058
]
],
[
[
999,
24,
1638
],
[
1638,
1,
1058
]
],
[
[
999,
24,
479
],
[
479,
40,
1058
]
],
[
[
999,
23,
460
],
[
460,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moexipril"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Moexipril (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Moexipril... |
DB00682 | DB01182 | 126 | 371 | [
"DDInter1951",
"DDInter1534"
] | Warfarin | Propafenone | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Moderate | 1 | [
[
[
126,
24,
371
]
],
[
[
126,
1,
847
],
[
847,
1,
371
]
],
[
[
126,
23,
271
],
[
271,
1,
371
]
],
[
[
126,
36,
97
],
[
97,
1,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
]
],
[
[
"Warfarin",
"{u} (Compound) resembles {v} (Compound)",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} (Compound) resembles... | Warfarin (Compound) resembles Atomoxetine (Compound) and Atomoxetine (Compound) resembles Propafenone (Compound)
Warfarin may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron (Compound) resembles Propafenone (Compound)
Warfarin (Compound) resembles Oxaprozin (Compound)... |
DB00370 | DB01169 | 1,251 | 57 | [
"DDInter1230",
"DDInter120"
] | Mirtazapine | Arsenic trioxide | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Major | 2 | [
[
[
1251,
25,
57
]
],
[
[
1251,
6,
8374
],
[
8374,
45,
57
]
],
[
[
1251,
23,
112
],
[
112,
23,
57
]
],
[
[
1251,
24,
603
],
[
603,
6... | [
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Mirtazapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Mirtazapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Arsenic trioxide (Compound)
Mirtazapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Arsenic trioxide
Mi... |
DB00629 | DB01285 | 390 | 708 | [
"DDInter844",
"DDInter445"
] | Guanabenz | Corticotropin | An alpha-2 selective adrenergic agonist used as an antihypertensive agent. [PubChem] | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
390,
24,
708
]
],
[
[
390,
1,
1364
],
[
1364,
24,
708
]
],
[
[
390,
24,
1450
],
[
1450,
63,
708
]
],
[
[
390,
63,
1648
],
[
1648,
... | [
[
[
"Guanabenz",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Guanabenz",
"{u} (Compound) resembles {v} (Compound)",
"Guanfacine"
],
[
"Guanfacine",
"{u} may cause a modera... | Guanabenz (Compound) resembles Guanfacine (Compound) and Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction tha... |
DB01066 | DB06723 | 1,462 | 115 | [
"DDInter316",
"DDInter58"
] | Cefditoren | Aluminum hydroxide | Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma. | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
1462,
24,
115
]
],
[
[
1462,
63,
1194
],
[
1194,
23,
115
]
],
[
[
1462,
1,
1024
],
[
1024,
24,
115
]
],
[
[
1462,
63,
1096
],
[
1096,
... | [
[
[
"Cefditoren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Cefditoren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
],
... | Cefditoren may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Cefditoren (Compound) resembles Cefpodoxime (Compound) and Cefpodoxime may cause a moderate interaction th... |
DB00976 | DB09080 | 1,056 | 144 | [
"DDInter1758",
"DDInter1331"
] | Telithromycin | Olodaterol | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1056,
24,
144
]
],
[
[
1056,
25,
1011
],
[
1011,
24,
144
]
],
[
[
1056,
64,
11
],
[
11,
24,
144
]
],
[
[
1056,
63,
51
],
[
51,
2... | [
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fing... | Telithromycin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Telithromycin may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderat... |
DB00741 | DB00877 | 167 | 629 | [
"DDInter885",
"DDInter1678"
] | Hydrocortisone | Sirolimus | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
167,
24,
629
]
],
[
[
167,
6,
4973
],
[
4973,
45,
629
]
],
[
[
167,
7,
3163
],
[
3163,
46,
629
]
],
[
[
167,
18,
3169
],
[
3169,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compou... | Hydrocortisone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Hydrocortisone (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Sirolimus (Compound)
Hydrocortisone (Compound) downregulates SQSTM1 (Gene) and SQSTM1 (Gene) is upregulated by Sirolimus (Compound)
Hyd... |
DB08865 | DB13007 | 1,593 | 1,060 | [
"DDInter448",
"DDInter642"
] | Crizotinib | Enfortumab vedotin | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
1593,
24,
1060
]
],
[
[
1593,
25,
129
],
[
129,
23,
1060
]
],
[
[
1593,
63,
1439
],
[
1439,
24,
1060
]
],
[
[
1593,
24,
350
],
[
350,
... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"... | Crizotinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab ... |
DB00424 | DB00727 | 19 | 685 | [
"DDInter896",
"DDInter1304"
] | Hyoscyamine | Nitroglycerin | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Nitroglycerin, also known as glyceryl trinitrate, is an organic nitrate and a vasodilating agent that was first discovered in 1847. Originally used to dynamite, its antianginal effects were identified in the late 1860s after it produced headaches in factory workers while workers with angina pectoris or heart failure ex... | Minor | 0 | [
[
[
19,
23,
685
]
],
[
[
19,
21,
28691
],
[
28691,
60,
685
]
],
[
[
19,
24,
85
],
[
85,
23,
685
]
],
[
[
19,
24,
1511
],
[
1511,
62,... | [
[
[
"Hyoscyamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nitroglycerin"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is... | Hyoscyamine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Nitroglycerin (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a minor interaction that can limit clinical effects when taken with Nitrog... |
DB01132 | DB14761 | 1,130 | 242 | [
"DDInter1472",
"DDInter1578"
] | Pioglitazone | Remdesivir | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
1130,
24,
242
]
],
[
[
1130,
64,
1377
],
[
1377,
24,
242
]
],
[
[
1130,
24,
384
],
[
384,
24,
242
]
],
[
[
1130,
63,
482
],
[
482,
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Pioglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflu... | Pioglitazone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may ... |
DB00688 | DB00916 | 955 | 112 | [
"DDInter1251",
"DDInter1202"
] | Mycophenolate mofetil | Metronidazole | Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, ren... | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Moderate | 1 | [
[
[
955,
24,
112
]
],
[
[
955,
24,
458
],
[
458,
40,
112
]
],
[
[
955,
6,
3486
],
[
3486,
45,
112
]
],
[
[
955,
21,
29028
],
[
29028,
... | [
[
[
"Mycophenolate mofetil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]
],
[
[
"Mycophenolate mofetil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ti... | Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole and Tinidazole (Compound) resembles Metronidazole (Compound)
Mycophenolate mofetil (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Metronidazole (Compound)
Mycophenolate mofetil (Compound) cause... |
DB00222 | DB00960 | 245 | 887 | [
"DDInter825",
"DDInter1471"
] | Glimepiride | Pindolol | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Moderate | 1 | [
[
[
245,
24,
887
]
],
[
[
245,
24,
819
],
[
819,
40,
887
]
],
[
[
245,
24,
1148
],
[
1148,
63,
887
]
],
[
[
245,
24,
1121
],
[
1121,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
[
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol (Compound) resembles Pindolol (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that c... |
DB01169 | DB06402 | 57 | 1,079 | [
"DDInter120",
"DDInter1756"
] | Arsenic trioxide | Telavancin | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Major | 2 | [
[
[
57,
25,
1079
]
],
[
[
57,
62,
112
],
[
112,
23,
1079
]
],
[
[
57,
24,
657
],
[
657,
63,
1079
]
],
[
[
57,
63,
543
],
[
543,
24,
... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Telavancin
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Castor ... |
DB06402 | DB11113 | 1,079 | 657 | [
"DDInter1756",
"DDInter307"
] | Telavancin | Castor oil | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
1079,
24,
657
]
],
[
[
1079,
24,
927
],
[
927,
63,
657
]
],
[
[
1079,
24,
1491
],
[
1491,
24,
657
]
],
[
[
1079,
25,
985
],
[
985,
... | [
[
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Mid... |
DB00009 | DB04932 | 1,271 | 1,564 | [
"DDInter56",
"DDInter491"
] | Alteplase | Defibrotide | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Major | 2 | [
[
[
1271,
25,
1564
]
],
[
[
1271,
23,
297
],
[
297,
62,
1564
]
],
[
[
1271,
24,
914
],
[
914,
24,
1564
]
],
[
[
1271,
24,
41
],
[
41,
... | [
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Alteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u}... | Alteplase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Defibrotide
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause ... |
DB00747 | DB01203 | 1,442 | 699 | [
"DDInter1647",
"DDInter1255"
] | Scopolamine | Nadolol | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Moderate | 1 | [
[
[
1442,
24,
699
]
],
[
[
1442,
24,
729
],
[
729,
1,
699
]
],
[
[
1442,
6,
4973
],
[
4973,
45,
699
]
],
[
[
1442,
21,
28882
],
[
28882,
... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],
[
... | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Nadolol (Compound)
Scopolamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nadolol (Compound)
Scopolamine (Compound) causes Body temperature increased (Side Effect) a... |
DB01281 | DB11817 | 881 | 1,259 | [
"DDInter5",
"DDInter165"
] | Abatacept | Baricitinib | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS mo... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
881,
25,
1259
]
],
[
[
881,
23,
1193
],
[
1193,
23,
1259
]
],
[
[
881,
62,
1461
],
[
1461,
23,
1259
]
],
[
[
881,
24,
949
],
[
949,
... | [
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Abatacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluc... | Abatacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Abatacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitami... |
DB06674 | DB13007 | 908 | 1,060 | [
"DDInter837",
"DDInter642"
] | Golimumab | Enfortumab vedotin | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Major | 2 | [
[
[
908,
25,
1060
]
],
[
[
908,
24,
1593
],
[
1593,
24,
1060
]
],
[
[
908,
63,
1439
],
[
1439,
24,
1060
]
],
[
[
908,
25,
270
],
[
270,
... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Criz... | Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and ... |
DB00757 | DB04948 | 1,166 | 1,084 | [
"DDInter581",
"DDInter1083"
] | Dolasetron | Lofexidine | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Major | 2 | [
[
[
1166,
25,
1084
]
],
[
[
1166,
23,
112
],
[
112,
23,
1084
]
],
[
[
1166,
64,
618
],
[
618,
24,
1084
]
],
[
[
1166,
25,
774
],
[
774,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lofexidine"
]
],
[
[
"Dolasetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Dolasetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lofexidine
Dolasetron may lead to a major life threatening interaction when taken with Abarelix and Abarelix may cause a ... |
DB00468 | DB00750 | 1,424 | 490 | [
"DDInter1557",
"DDInter1519"
] | Quinine | Prilocaine (topiclal) | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Prilocaine is an amino acid amide in which N-propyl-DL-alanine and 2-methylaniline have combined to form the amide bond; used as a local anaesthetic. It has a role as a local anaesthetic and an anticonvulsant. It is an amino acid amide and a monocarboxylic acid amide. | Major | 2 | [
[
[
1424,
25,
490
]
],
[
[
1424,
21,
28789
],
[
28789,
60,
490
]
],
[
[
1424,
24,
1520
],
[
1520,
64,
490
]
],
[
[
1424,
25,
1455
],
[
145... | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prilocaine"
]
],
[
[
"Quinine",
"{u} (Compound) causes {v} (Side Effect)",
"Loss of consciousness"
],
[
"Loss of consciousness",
"{u} (Side Effect) is c... | Quinine may lead to a major life threatening interaction when taken with Prilocaine
Quinine (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Prilocaine (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Primaquine ... |
DB00421 | DB11921 | 443 | 1,019 | [
"DDInter1707",
"DDInter492"
] | Spironolactone | Deflazacort | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
443,
24,
1019
]
],
[
[
443,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
443,
1,
155
],
[
155,
24,
1019
]
],
[
[
443,
24,
355
],
[
355,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Spironolactone (Compound) resembles Fluoxymesterone (Compound) and Fluoxymesterone may cause a moderate inter... |
DB00421 | DB01249 | 443 | 258 | [
"DDInter1707",
"DDInter958"
] | Spironolactone | Iodixanol | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. | Moderate | 1 | [
[
[
443,
24,
258
]
],
[
[
443,
24,
497
],
[
497,
1,
258
]
],
[
[
443,
7,
2384
],
[
2384,
46,
258
]
],
[
[
443,
21,
28722
],
[
28722,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
],
... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Iohexol and Iohexol (Compound) resembles Iodixanol (Compound)
Spironolactone (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Iodixanol (Compound)
Spironolactone (Compound) causes Nausea (Side Effect) and ... |
DB06176 | DB15091 | 1,342 | 676 | [
"DDInter1616",
"DDInter1901"
] | Romidepsin | Upadacitinib | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
1342,
25,
676
]
],
[
[
1342,
63,
1461
],
[
1461,
23,
676
]
],
[
[
1342,
24,
1430
],
[
1430,
24,
676
]
],
[
[
1342,
25,
1593
],
[
1593,... | [
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E... | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipule... |
DB00307 | DB00446 | 1,101 | 597 | [
"DDInter202",
"DDInter351"
] | Bexarotene | Chloramphenicol | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Minor | 0 | [
[
[
1101,
23,
597
]
],
[
[
1101,
6,
6017
],
[
6017,
45,
597
]
],
[
[
1101,
21,
28787
],
[
28787,
60,
597
]
],
[
[
1101,
24,
479
],
[
479,
... | [
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound... | Bexarotene (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Chloramphenicol (Compound)
Bexarotene (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Chloramphenicol (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Donepez... |
DB01067 | DB01364 | 959 | 22 | [
"DDInter826",
"DDInter650"
] | Glipizide | Ephedrine | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Moderate | 1 | [
[
[
959,
24,
22
]
],
[
[
959,
24,
1529
],
[
1529,
63,
22
]
],
[
[
959,
24,
280
],
[
280,
1,
22
]
],
[
[
959,
63,
1445
],
[
1445,
1,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
[
... | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine and ... |
DB00726 | DB09268 | 1,164 | 1,662 | [
"DDInter1876",
"DDInter1464"
] | Trimipramine | Picosulfuric acid | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1164,
24,
1662
]
],
[
[
1164,
24,
484
],
[
484,
63,
1662
]
],
[
[
1164,
25,
1618
],
[
1618,
24,
1662
]
],
[
[
1164,
63,
73
],
[
73,
... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
... | Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Trimipramine may lead to a major life threatening interaction when taken with Cabozantinib and Caboza... |
DB00514 | DB09291 | 506 | 741 | [
"DDInter527",
"DDInter1615"
] | Dextromethorphan | Rolapitant | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
506,
24,
741
]
],
[
[
506,
24,
924
],
[
924,
24,
741
]
],
[
[
506,
64,
758
],
[
758,
24,
741
]
],
[
[
506,
24,
214
],
[
214,
63,... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone and Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Dextromethorphan may lead to a major life threatening interaction when taken with Fluoxetine and Fluoxet... |
DB00465 | DB08875 | 886 | 1,618 | [
"DDInter1010",
"DDInter262"
] | Ketorolac | Cabozantinib | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
886,
25,
1618
]
],
[
[
886,
24,
384
],
[
384,
63,
1618
]
],
[
[
886,
24,
850
],
[
850,
24,
1618
]
],
[
[
886,
25,
629
],
[
629,
... | [
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib... | Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin a... |
DB05294 | DB08916 | 1,069 | 26 | [
"DDInter1917",
"DDInter32"
] | Vandetanib | Afatinib | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal grow... | Moderate | 1 | [
[
[
1069,
35,
26
]
],
[
[
1069,
1,
883
],
[
883,
40,
26
]
],
[
[
1069,
6,
18147
],
[
18147,
45,
26
]
],
[
[
1069,
6,
2065
],
[
2065,
... | [
[
[
"Vandetanib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Vandetanib",
"{u} (Compound) resembles {v} (Compound)",
"Gefitinib"
],
[
"Ge... | Vandetanib (Compound) resembles Afatinib (Compound) and
Vandetanib (Compound) resembles Gefitinib (Compound) and Gefitinib (Compound) resembles Afatinib (Compound)
Vandetanib (Compound) binds EPHA6 (Gene) and EPHA6 (Gene) is bound by Afatinib (Compound)
Vandetanib (Compound) binds SRC (Gene) and SRC (Gene) is upregulat... |
DB00264 | DB06663 | 88 | 1,154 | [
"DDInter1200",
"DDInter1398"
] | Metoprolol | Pasireotide | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
88,
24,
1154
]
],
[
[
88,
63,
966
],
[
966,
40,
1154
]
],
[
[
88,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
88,
24,
959
],
[
959,
... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
... | Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide (Compound) resembles Pasireotide (Compound)
Metoprolol (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Metoprolol may cause a moderate ... |
DB00470 | DB01115 | 530 | 336 | [
"DDInter601",
"DDInter1291"
] | Dronabinol | Nifedipine | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Moderate | 1 | [
[
[
530,
24,
336
]
],
[
[
530,
63,
1428
],
[
1428,
1,
336
]
],
[
[
530,
24,
1081
],
[
1081,
40,
336
]
],
[
[
530,
24,
409
],
[
409,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Nifedipine (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) resembles Nifedipine (Compound... |
DB01377 | DB11943 | 1,283 | 255 | [
"DDInter1119",
"DDInter495"
] | Magnesium oxide | Delafloxacin | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Moderate | 1 | [
[
[
1283,
24,
255
]
],
[
[
1283,
62,
60
],
[
60,
23,
255
]
],
[
[
1283,
63,
1479
],
[
1479,
24,
255
]
],
[
[
1283,
24,
1596
],
[
1596,
... | [
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
]
],
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
... | Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecitabine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Acetylsal... |
DB00039 | DB05015 | 1,253 | 1,077 | [
"DDInter1380",
"DDInter174"
] | Palifermin | Belinostat | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Moderate | 1 | [
[
[
1253,
24,
1077
]
],
[
[
1253,
24,
482
],
[
482,
24,
1077
]
],
[
[
1253,
24,
1250
],
[
1250,
63,
1077
]
],
[
[
1253,
24,
1064
],
[
1064... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belinostat"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopan... |
DB00434 | DB01011 | 13 | 925 | [
"DDInter459",
"DDInter1204"
] | Cyproheptadine | Metyrapone | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | An inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome. | Moderate | 1 | [
[
[
13,
24,
925
]
],
[
[
13,
21,
28766
],
[
28766,
60,
925
]
],
[
[
13,
21,
28766
],
[
28766,
60,
265
],
[
265,
40,
925
]
],
[
[
13,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metyrapone"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Eff... | Cyproheptadine (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Metyrapone (Compound)
Cyproheptadine (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Niacin (Compound) and Niacin (Compound) resembles Metyrapone (Compound)
Cyproheptadine (Compou... |
DB00204 | DB11718 | 228 | 927 | [
"DDInter580",
"DDInter640"
] | Dofetilide | Encorafenib | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
228,
25,
927
]
],
[
[
228,
23,
112
],
[
112,
23,
927
]
],
[
[
228,
24,
720
],
[
720,
24,
927
]
],
[
[
228,
62,
1324
],
[
1324,
2... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Dofetilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mi... |
DB00176 | DB08899 | 529 | 129 | [
"DDInter770",
"DDInter649"
] | Fluvoxamine | Enzalutamide | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
529,
24,
129
]
],
[
[
529,
6,
8374
],
[
8374,
45,
129
]
],
[
[
529,
21,
28703
],
[
28703,
60,
129
]
],
[
[
529,
24,
608
],
[
608,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Fluvoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Fluvoxamine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and ... |
DB11986 | DB14568 | 484 | 982 | [
"DDInter648",
"DDInter1000"
] | Entrectinib | Ivosidenib | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
484,
25,
982
]
],
[
[
484,
62,
271
],
[
271,
23,
982
]
],
[
[
484,
63,
1101
],
[
1101,
23,
982
]
],
[
[
484,
63,
1081
],
[
1081,
... | [
[
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Entrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron... | Entrectinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarote... |
DB00518 | DB00564 | 510 | 1,236 | [
"DDInter35",
"DDInter293"
] | Albendazole | Carbamazepine | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Moderate | 1 | [
[
[
510,
24,
1236
]
],
[
[
510,
23,
307
],
[
307,
1,
1236
]
],
[
[
510,
63,
362
],
[
362,
1,
1236
]
],
[
[
510,
24,
1335
],
[
1335,
... | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Albendazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
... | Albendazole may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Carbamazepine (Compound)
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Carbamazepine (Compound... |
DB00346 | DB00486 | 472 | 1,614 | [
"DDInter44",
"DDInter1253"
] | Alfuzosin | Nabilone | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
472,
24,
1614
]
],
[
[
472,
24,
530
],
[
530,
1,
1614
]
],
[
[
472,
21,
28789
],
[
28789,
60,
1614
]
],
[
[
472,
24,
999
],
[
999,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
... | Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Alfuzosin (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Nabilone (Compound)
Alfuzosin may cause a mode... |
DB00701 | DB01268 | 1,091 | 1,151 | [
"DDInter90",
"DDInter1731"
] | Amprenavir | Sunitinib | Amprenavir is a protease inhibitor used to treat HIV infection. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
1091,
24,
1151
]
],
[
[
1091,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
1091,
21,
29209
],
[
29209,
60,
1151
]
],
[
[
1091,
25,
112
],
[
11... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Amprenavir",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Amprenavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Amprenavir (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Sunitinib (Compound)
Amprenavir may lead to a major life threatening interaction when taken with Metronidazole and Metronidazole may caus... |
DB00619 | DB01403 | 1,419 | 9 | [
"DDInter909",
"DDInter1175"
] | Imatinib | Methotrimeprazine | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
1419,
24,
9
]
],
[
[
1419,
24,
1178
],
[
1178,
40,
9
]
],
[
[
1419,
24,
1164
],
[
1164,
1,
9
]
],
[
[
1419,
25,
684
],
[
684,
40... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Metho... |
DB00323 | DB01168 | 1,062 | 1,053 | [
"DDInter1829",
"DDInter1526"
] | Tolcapone | Procarbazine | Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
1062,
25,
1053
]
],
[
[
1062,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1062,
23,
126
],
[
126,
23,
1053
]
],
[
[
1062,
24,
100
],
[
100... | [
[
[
"Tolcapone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Tolcapone",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compou... | Tolcapone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Tolcapone may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Tolc... |
DB00363 | DB00692 | 695 | 274 | [
"DDInter419",
"DDInter1448"
] | Clozapine | Phentolamine | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | Moderate | 1 | [
[
[
695,
24,
274
]
],
[
[
695,
6,
5372
],
[
5372,
45,
274
]
],
[
[
695,
24,
1296
],
[
1296,
62,
274
]
],
[
[
695,
63,
1685
],
[
1685,
... | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"ADRA2A"
],
[
"ADRA2A",
"{u} (Gene) is bound by {v} (Compound)",... | Clozapine (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) is bound by Phentolamine (Compound)
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a minor interaction that can limit clinical effects when taken with Phentolamine
Clozap... |
DB01261 | DB08869 | 170 | 162 | [
"DDInter1679",
"DDInter1773"
] | Sitagliptin | Tesamorelin | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and... | Moderate | 1 | [
[
[
170,
24,
162
]
],
[
[
170,
63,
245
],
[
245,
24,
162
]
],
[
[
170,
23,
52
],
[
52,
63,
162
]
],
[
[
170,
24,
1254
],
[
1254,
24,... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tesamorelin"
]
],
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Tesamorelin
Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide and Du... |
DB00317 | DB01406 | 883 | 984 | [
"DDInter810",
"DDInter472"
] | Gefitinib | Danazol | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Moderate | 1 | [
[
[
883,
24,
984
]
],
[
[
883,
6,
8374
],
[
8374,
45,
984
]
],
[
[
883,
18,
3833
],
[
3833,
46,
984
]
],
[
[
883,
7,
4759
],
[
4759,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Gefitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Danazol (Compound)
Gefitinib (Compound) downregulates JMJD6 (Gene) and JMJD6 (Gene) is upregulated by Danazol (Compound)
Gefitinib (Compound) upregulates SERPINA3 (Gene) and SERPINA3 (Gene) is upregulated by Danazol (Compound)
Gefitinib (Compound) d... |
DB00365 | DB13928 | 839 | 1,385 | [
"DDInter842",
"DDInter1660"
] | Grepafloxacin | Semaglutide | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
839,
24,
1385
]
],
[
[
839,
25,
1154
],
[
1154,
24,
1385
]
],
[
[
839,
24,
1476
],
[
1476,
24,
1385
]
],
[
[
839,
64,
1179
],
[
1179,
... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pa... | Grepafloxacin may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib m... |
DB08864 | DB12130 | 786 | 1,017 | [
"DDInter1595",
"DDInter1094"
] | Rilpivirine | Lorlatinib | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
786,
24,
1017
]
],
[
[
786,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
786,
63,
1491
],
[
1491,
24,
1017
]
],
[
[
786,
64,
11
],
[
11,
... | [
[
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midos... |
DB01128 | DB09083 | 918 | 880 | [
"DDInter204",
"DDInter996"
] | Bicalutamide | Ivabradine | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
918,
25,
880
]
],
[
[
918,
63,
480
],
[
480,
24,
880
]
],
[
[
918,
24,
1478
],
[
1478,
24,
880
]
],
[
[
918,
24,
159
],
[
159,
6... | [
[
[
"Bicalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formot... | Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Iva... |
DB00574 | DB09039 | 121 | 1,670 | [
"DDInter717",
"DDInter629"
] | Fenfluramine | Eliglustat | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
121,
24,
1670
]
],
[
[
121,
23,
479
],
[
479,
23,
1670
]
],
[
[
121,
24,
1409
],
[
1409,
24,
1670
]
],
[
[
121,
63,
87
],
[
87,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Fenfluramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
... | Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban m... |
DB00981 | DB04861 | 1,528 | 1,592 | [
"DDInter1462",
"DDInter1271"
] | Physostigmine | Nebivolol | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Moderate | 1 | [
[
[
1528,
24,
1592
]
],
[
[
1528,
21,
28653
],
[
28653,
60,
1592
]
],
[
[
1528,
24,
1476
],
[
1476,
63,
1592
]
],
[
[
1528,
63,
1123
],
[
... | [
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Physostigmine",
"{u} (Compound) causes {v} (Side Effect)",
"Bradycardia"
],
[
"Bradycardia",
"{u} (Side Effect... | Physostigmine (Compound) causes Bradycardia (Side Effect) and Bradycardia (Side Effect) is caused by Nebivolol (Compound)
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00207 | DB09082 | 1,570 | 659 | [
"DDInter157",
"DDInter1934"
] | Azithromycin | Vilanterol | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1570,
24,
659
]
],
[
[
1570,
24,
927
],
[
927,
63,
659
]
],
[
[
1570,
25,
1069
],
[
1069,
24,
659
]
],
[
[
1570,
24,
485
],
[
485,
... | [
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
... | Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Azithromycin may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may ... |
DB00361 | DB14444 | 134 | 151 | [
"DDInter1939",
"DDInter924"
] | Vinorelbine | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
134,
24,
151
]
],
[
[
134,
63,
66
],
[
66,
24,
151
]
],
[
[
134,
24,
1619
],
[
1619,
24,
151
]
],
[
[
134,
25,
375
],
[
375,
24,... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Vinorelbine may cause a moderate int... |
DB11793 | DB12941 | 738 | 466 | [
"DDInter1297",
"DDInter481"
] | Niraparib | Darolutamide | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Moderate | 1 | [
[
[
738,
24,
466
]
],
[
[
738,
63,
1623
],
[
1623,
23,
466
]
],
[
[
738,
24,
484
],
[
484,
23,
466
]
],
[
[
738,
63,
1155
],
[
1155,
... | [
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
],
... | Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium and Isavuconazonium may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib a... |
DB00783 | DB00877 | 1,438 | 629 | [
"DDInter679",
"DDInter1678"
] | Estradiol | Sirolimus | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
1438,
24,
629
]
],
[
[
1438,
6,
4973
],
[
4973,
45,
629
]
],
[
[
1438,
18,
2493
],
[
2493,
46,
629
]
],
[
[
1438,
7,
9489
],
[
9489,
... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Estradiol",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Estradiol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Estradiol (Compound) downregulates HIST2H2BE (Gene) and HIST2H2BE (Gene) is upregulated by Sirolimus (Compound)
Estradiol (Compound) upregulates WIF1 (Gene) and WIF1 (Gene) is upregulated by Sirolimus (Compound)
Estradiol (Compoun... |
DB00881 | DB06779 | 954 | 365 | [
"DDInter1554",
"DDInter470"
] | Quinapril | Dalteparin | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Moderate | 1 | [
[
[
954,
24,
365
]
],
[
[
954,
63,
305
],
[
305,
24,
365
]
],
[
[
954,
40,
610
],
[
610,
24,
365
]
],
[
[
954,
63,
1274
],
[
1274,
2... | [
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalteparin"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli... | Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Quinapril (Compound) resembles Enalapril (Compound) and Enalapril may cause... |
DB00647 | DB01619 | 675 | 830 | [
"DDInter528",
"DDInter1441"
] | Dextropropoxyphene | Phenindamine | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Major | 2 | [
[
[
675,
25,
830
]
],
[
[
675,
25,
537
],
[
537,
40,
830
]
],
[
[
675,
64,
13
],
[
13,
24,
830
]
],
[
[
675,
25,
104
],
[
104,
1,
... | [
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenindamine"
]
],
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyclizine"
],
[
"Cyclizin... | Dextropropoxyphene may lead to a major life threatening interaction when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Dextropropoxyphene may lead to a major life threatening interaction when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exace... |
DB08938 | DB11703 | 1,384 | 405 | [
"DDInter1112",
"DDInter9"
] | Magaldrate | Acalabrutinib | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
1384,
24,
405
]
],
[
[
1384,
63,
478
],
[
478,
24,
405
]
],
[
[
1384,
62,
1194
],
[
1194,
24,
405
]
],
[
[
1384,
63,
463
],
[
463,
... | [
[
[
"Magaldrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Magaldrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Magaldrate may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitid... |
DB01142 | DB08875 | 1,264 | 1,618 | [
"DDInter593",
"DDInter262"
] | Doxepin | Cabozantinib | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1264,
25,
1618
]
],
[
[
1264,
62,
112
],
[
112,
23,
1618
]
],
[
[
1264,
63,
307
],
[
307,
24,
1618
]
],
[
[
1264,
24,
1032
],
[
1032,
... | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole... | Doxepin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil... |
DB00549 | DB08864 | 522 | 786 | [
"DDInter1955",
"DDInter1595"
] | Zafirlukast | Rilpivirine | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Moderate | 1 | [
[
[
522,
24,
786
]
],
[
[
522,
24,
655
],
[
655,
1,
786
]
],
[
[
522,
6,
8374
],
[
8374,
45,
786
]
],
[
[
522,
21,
28698
],
[
28698,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine (Compound) resembles Rilpivirine (Compound)
Zafirlukast (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound)
Zafirlukast (Compound) causes Insomnia (Side Effect) and Insom... |
DB00083 | DB00748 | 677 | 662 | [
"DDInter225",
"DDInter297"
] | Botulinum toxin type A | Carbinoxamine | In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperf... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
677,
24,
662
]
],
[
[
677,
24,
1594
],
[
1594,
24,
662
]
],
[
[
677,
24,
830
],
[
830,
63,
662
]
],
[
[
677,
24,
832
],
[
832,
7... | [
[
[
"Botulinum toxin type A",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Botulinum toxin type A",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"... | Botulinum toxin type A may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Botulinum toxin type A may cause a moderate interaction that could exacerbate diseases when taken... |
DB00476 | DB08824 | 109 | 591 | [
"DDInter608",
"DDInter959"
] | Duloxetine | Ioflupane I-123 | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes. | Moderate | 1 | [
[
[
109,
24,
591
]
],
[
[
109,
6,
2437
],
[
2437,
45,
591
]
],
[
[
109,
21,
29305
],
[
29305,
60,
591
]
],
[
[
109,
40,
758
],
[
758,
... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Duloxetine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A3"
],
[
"SLC6A3",
"{u} (Gene) is bound by {v} (Compou... | Duloxetine (Compound) binds SLC6A3 (Gene) and SLC6A3 (Gene) is bound by Ioflupane I-123 (Compound)
Duloxetine (Compound) causes Dysgeusia (Side Effect) and Dysgeusia (Side Effect) is caused by Ioflupane I-123 (Compound)
Duloxetine (Compound) resembles Fluoxetine (Compound) and Fluoxetine may cause a moderate interactio... |
DB01222 | DB14711 | 617 | 779 | [
"DDInter246",
"DDInter1680"
] | Budesonide | Smallpox (Vaccinia) Vaccine, Live | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
617,
25,
779
]
],
[
[
617,
64,
1064
],
[
1064,
25,
779
]
],
[
[
617,
24,
478
],
[
478,
25,
779
]
],
[
[
617,
63,
1560
],
[
1560,
... | [
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cl... | Budesonide may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may ... |
DB00095 | DB08826 | 66 | 1,292 | [
"DDInter623",
"DDInter489"
] | Efalizumab | Deferiprone | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
66,
25,
1292
]
],
[
[
66,
23,
1193
],
[
1193,
63,
1292
]
],
[
[
66,
24,
482
],
[
482,
25,
1292
]
],
[
[
66,
24,
1619
],
[
1619,
... | [
[
[
"Efalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gl... | Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and... |
DB08871 | DB14444 | 36 | 151 | [
"DDInter666",
"DDInter924"
] | Eribulin | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
36,
24,
151
]
],
[
[
36,
63,
66
],
[
66,
24,
151
]
],
[
[
36,
24,
1619
],
[
1619,
24,
151
]
],
[
[
36,
25,
375
],
[
375,
24,
... | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exace... | Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Eribulin may cause a moderate interacti... |
DB09073 | DB10989 | 951 | 496 | [
"DDInter1379",
"DDInter858"
] | Palbociclib | Hepatitis A Vaccine | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
951,
24,
496
]
],
[
[
951,
63,
4
],
[
4,
24,
496
]
],
[
[
951,
64,
976
],
[
976,
24,
496
]
],
[
[
951,
24,
270
],
[
270,
63,
... | [
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepe... | Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Palbociclib may lead to a major life threatening interaction when taken ... |
DB01619 | DB11632 | 830 | 580 | [
"DDInter1441",
"DDInter1343"
] | Phenindamine | Opicapone | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) in... | Moderate | 1 | [
[
[
830,
24,
580
]
],
[
[
830,
40,
104
],
[
104,
24,
580
]
],
[
[
830,
1,
1219
],
[
1219,
24,
580
]
],
[
[
830,
63,
401
],
[
401,
24... | [
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Phenindamine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a ... | Phenindamine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Phenindamine (Compound) resembles Azatadine (Compound) and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Opicap... |
DB00382 | DB00398 | 62 | 79 | [
"DDInter1734",
"DDInter1702"
] | Tacrine | Sorafenib | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Moderate | 1 | [
[
[
62,
24,
79
]
],
[
[
62,
24,
112
],
[
112,
62,
79
]
],
[
[
62,
24,
543
],
[
543,
63,
79
]
],
[
[
62,
63,
521
],
[
521,
24,
... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sorafenib
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamid... |
DB01229 | DB11627 | 973 | 1,367 | [
"DDInter1377",
"DDInter860"
] | Paclitaxel | Hepatitis B Vaccine (Recombinant) | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
973,
24,
1367
]
],
[
[
973,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
973,
24,
1480
],
[
1480,
24,
1367
]
],
[
[
973,
25,
375
],
[
375,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
... | Paclitaxel may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and ... |
DB08880 | DB10276 | 1,510 | 1,624 | [
"DDInter1771",
"DDInter1623"
] | Teriflunomide | Rotavirus vaccine | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
1510,
25,
1624
]
],
[
[
1510,
64,
617
],
[
617,
24,
1624
]
],
[
[
1510,
64,
552
],
[
552,
25,
1624
]
],
[
[
1510,
25,
1583
],
[
1583,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
],
[
"Budesonide",... | Teriflunomide may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine
Teriflunomide may lead to a major life threatening interaction when taken with Carmustine and Carmustine may lead to ... |
DB00163 | DB00443 | 1,461 | 251 | [
"DDInter1943",
"DDInter195"
] | Vitamin E | Betamethasone | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Minor | 0 | [
[
[
1461,
23,
251
]
],
[
[
1461,
23,
617
],
[
617,
40,
251
]
],
[
[
1461,
23,
167
],
[
167,
1,
251
]
],
[
[
1461,
7,
2384
],
[
2384,
... | [
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Betamethasone"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Budesonide"
],
[
... | Vitamin E may cause a minor interaction that can limit clinical effects when taken with Budesonide and Budesonide (Compound) resembles Betamethasone (Compound)
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Betamethasone (Co... |
DB01006 | DB04574 | 300 | 177 | [
"DDInter1040",
"DDInter684"
] | Letrozole | Estrone sulfate (topical) | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole... | Estrone 3-sulfate is a steroid sulfate that is the 3-sulfate of estrone. It has a role as a human metabolite and a mouse metabolite. It is a 17-oxo steroid and a steroid sulfate. It is functionally related to an estrone. It is a conjugate acid of an estrone 3-sulfate(1-). It derives from a hydride of an estrane. | Moderate | 1 | [
[
[
300,
24,
177
]
],
[
[
300,
63,
380
],
[
380,
1,
177
]
],
[
[
300,
24,
35
],
[
35,
1,
177
]
],
[
[
300,
6,
8374
],
[
8374,
45,
... | [
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone sulfate"
]
],
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated estrogens"
... | Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Estrone sulfate
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens (Compound) resembles Estrone sulfate (Compound)
Letrozole may cause a moderate... |
DB06448 | DB08820 | 171 | 1,478 | [
"DDInter1087",
"DDInter997"
] | Lonafarnib | Ivacaftor | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Major | 2 | [
[
[
171,
25,
1478
]
],
[
[
171,
25,
1135
],
[
1135,
62,
1478
]
],
[
[
171,
64,
543
],
[
543,
24,
1478
]
],
[
[
171,
63,
1411
],
[
1411,
... | [
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may ... | Lonafarnib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Lonafarnib may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interacti... |
DB00530 | DB00661 | 1,195 | 122 | [
"DDInter667",
"DDInter1928"
] | Erlotinib | Verapamil | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Moderate | 1 | [
[
[
1195,
24,
122
]
],
[
[
1195,
6,
12523
],
[
12523,
45,
122
]
],
[
[
1195,
7,
15855
],
[
15855,
46,
122
]
],
[
[
1195,
21,
28809
],
[
28... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
]
],
[
[
"Erlotinib",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Erlotinib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Verapamil (Compound)
Erlotinib (Compound) upregulates SESN1 (Gene) and SESN1 (Gene) is upregulated by Verapamil (Compound)
Erlotinib (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Verapamil (Compound)
Erlotinib ma... |
DB01221 | DB04837 | 1,190 | 649 | [
"DDInter1007",
"DDInter407"
] | Ketamine | Clofedanol | Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
1190,
24,
649
]
],
[
[
1190,
63,
1376
],
[
1376,
24,
649
]
],
[
[
1190,
63,
832
],
[
832,
40,
649
]
],
[
[
1190,
24,
820
],
[
820,
... | [
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
... | Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine ... |
DB01253 | DB14568 | 628 | 982 | [
"DDInter664",
"DDInter1000"
] | Ergometrine | Ivosidenib | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
628,
24,
982
]
],
[
[
628,
63,
1101
],
[
1101,
23,
982
]
],
[
[
628,
24,
1478
],
[
1478,
24,
982
]
],
[
[
628,
1,
826
],
[
826,
... | [
[
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaft... |
DB00761 | DB00902 | 1,621 | 104 | [
"DDInter1497",
"DDInter1168"
] | Potassium chloride | Methdilazine | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Major | 2 | [
[
[
1621,
25,
104
]
],
[
[
1621,
64,
13
],
[
13,
24,
104
]
],
[
[
1621,
25,
820
],
[
820,
1,
104
]
],
[
[
1621,
25,
537
],
[
537,
40... | [
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methdilazine"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyproheptadine"
],
[
"Cyp... | Potassium chloride may lead to a major life threatening interaction when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Potassium chloride may lead to a major life threatening interaction when taken with Alimemazine and Alimemazi... |
DB00687 | DB00983 | 870 | 480 | [
"DDInter747",
"DDInter776"
] | Fludrocortisone | Formoterol | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Minor | 0 | [
[
[
870,
23,
480
]
],
[
[
870,
23,
1148
],
[
1148,
63,
480
]
],
[
[
870,
63,
1523
],
[
1523,
25,
480
]
],
[
[
870,
21,
29170
],
[
29170,
... | [
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Formoterol"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isoprenaline"
],
... | Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Labetalol... |
DB00889 | DB01236 | 1,133 | 679 | [
"DDInter840",
"DDInter1664"
] | Granisetron | Sevoflurane | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Moderate | 1 | [
[
[
1133,
24,
679
]
],
[
[
1133,
63,
1262
],
[
1262,
40,
679
]
],
[
[
1133,
6,
8374
],
[
8374,
45,
679
]
],
[
[
1133,
21,
28677
],
[
28677... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perflutren"
],
[... | Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Perflutren and Perflutren (Compound) resembles Sevoflurane (Compound)
Granisetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sevoflurane (Compound)
Granisetron (Compound) causes Hiccups (Side Effect) and Hiccup... |
DB00357 | DB14881 | 1,051 | 180 | [
"DDInter71",
"DDInter1329"
] | Aminoglutethimide | Oliceridine | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Major | 2 | [
[
[
1051,
25,
180
]
],
[
[
1051,
24,
124
],
[
124,
24,
180
]
],
[
[
1051,
62,
1101
],
[
1101,
24,
180
]
],
[
[
1051,
24,
741
],
[
741,
... | [
[
[
"Aminoglutethimide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Bexarotene... |
DB00697 | DB01041 | 876 | 770 | [
"DDInter1821",
"DDInter1789"
] | Tizanidine | Thalidomide | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
876,
24,
770
]
],
[
[
876,
6,
7950
],
[
7950,
45,
770
]
],
[
[
876,
21,
29598
],
[
29598,
60,
770
]
],
[
[
876,
24,
609
],
[
609,
... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Tizanidine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)"... | Tizanidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Thalidomide (Compound)
Tizanidine (Compound) causes Cellulitis (Side Effect) and Cellulitis (Side Effect) is caused by Thalidomide (Compound)
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin ... |
DB01224 | DB06788 | 623 | 1,616 | [
"DDInter1553",
"DDInter864"
] | Quetiapine | Histrelin | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
623,
24,
1616
]
],
[
[
623,
62,
112
],
[
112,
23,
1616
]
],
[
[
623,
24,
1342
],
[
1342,
24,
1616
]
],
[
[
623,
63,
1179
],
[
1179,
... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Quetiapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Quetiapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romid... |
DB11348 | DB12035 | 1,065 | 943 | [
"DDInter279",
"DDInter1641"
] | Calcium Phosphate | Sarecycline | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label]. | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Moderate | 1 | [
[
[
1065,
24,
943
]
],
[
[
1065,
63,
1014
],
[
1014,
23,
126
],
[
126,
24,
943
]
],
[
[
1065,
63,
819
],
[
819,
62,
417
],
[
417,
24,
... | [
[
[
"Calcium Phosphate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Calcium Phosphate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide... | Calcium Phosphate may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.